Anti-PD-1 therapy in advanced malignant liver tumor-induced type-1 diabetes mellitus: a case report
10.3760/cma.j.cn501113-20191124-00430
- VernacularTitle:抗PD-1治疗晚期肝恶性肿瘤诱发1型糖尿病1例
- Author:
Tao HE
1
;
Xiangbo ZHANG
;
Yunxia FEI
;
Lin GAO
;
Lin GONG
;
Qiuling ZHANG
;
Gongying CHEN
Author Information
1. 杭州师范大学 310011
- Keywords:
Type 1 diabetes mellit;
Immune checkpoint inhibitors;
Immune-related adverse events;
Programmed death 1
- From:
Chinese Journal of Hepatology
2020;28(6):518-520
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitor (ICI) has been emerged as a major breakthrough in tumor immunotherapy, but its unique mechanism of action has also led to a number of immune-related adverse events (irAE). Type 1 diabetes mellitus (T1DM) is one of the rarest irAEs. This paper reports a case of advanced malignant liver tumor-induced T1DM who received second-line anti-PD-1 therapy and showed initial symptoms of hyperosmolar coma and hyperglycemia. In addition, the relevant literature at home and abroad was collected and reviewed, and the clinical characteristics of T1DM induced by anti-PD-1 therapy were summarized with a view to achieve early detection, diagnosis and treatment.
